Literature DB >> 8534529

Clinical trials and quality of life assessment: the nurses' viewpoint.

C Molin1, C Arrigo.   

Abstract

The rationale for quality of life assessment has been largely developed in the literature. Quality of life is an important concept in the oncology environment because the physical, psychological and social wellbeing of patients are affected both by the disease and the related treatments. The relevance of quality of life assessment to nursing clinical practice has been discussed by several authors. There is a need to use more valid and reliable instruments to plan appropriate nursing care, to evaluate and document the effect of nursing interventions. In clinical trials, quality of life assessment is being used increasingly to predict patients' outcomes and to evaluate medical and nursing interventions. Nurses' viewpoints of potential benefits and pitfalls related to quality of life assessment are discussed. Among the benefits, it is usually considered that therapeutic interventions might be improved. These could be adjusted and individualised and the need for supportive care interventions might be evaluated more accurately. As for the pitfalls, the quality of life evaluation causes an extra burden if its implementation is not properly co-ordinated and if poor or incomplete guidelines are provided to patients and staff. Proposals for implementing effective quality of life assessment in clinical trials are discussed. Basic requirements, such as preliminary instructions, guidelines for administration of the questionnaire and proposals for reducing missing evaluations, are presented.

Entities:  

Mesh:

Year:  1995        PMID: 8534529     DOI: 10.1016/0959-8049(95)00495-5

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  1 in total

1.  Patient-reported outcome (PRO) assessment in clinical trials: a systematic review of guidance for trial protocol writers.

Authors:  Melanie Calvert; Derek Kyte; Helen Duffy; Adrian Gheorghe; Rebecca Mercieca-Bebber; Jonathan Ives; Heather Draper; Michael Brundage; Jane Blazeby; Madeleine King
Journal:  PLoS One       Date:  2014-10-15       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.